Navigation Links
Dendreon Reports First Quarter 2009 Financial Results
Date:5/6/2009

  • Presented data from the PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 study suggesting that PROVENGE induces long-term memory immune responses that are durable and can be maintained following boosting. The results of the study also indicate that CD54 upregulation on Antigen Presenting Cells (APC), a measure of product potency, is a correlate of immune activation. P-11 is an ongoing Phase 3 clinical trial designed to evaluate the safety and biologic activity of PROVENGE in patients with non-metastatic androgen-dependent (hormone sensitive) prostate cancer who have had a prostate-specific antigen (PSA) recurrence following surgical removal of the prostate.

  • "The significant increase in overall survival demonstrated in our Phase 3 IMPACT trial for PROVENGE is a major milestone for the company and puts us one step closer to making PROVENGE available to patients with prostate cancer who currently have few appealing treatment options," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We look forward to reviewing our commercialization plans for PROVENGE in more detail during a webcast analyst day this summer."

    In lieu of a conference call, the Company will present at several upcoming investor conferences that will be webcast, three of which are later this month and include:

    • Bank of America / Merrill Lynch 2009 Health Care Conference on May 12, 2009
    • Deutsche Bank 34th Annual Healthcare Conference on May 19, 2009
    • Leerink Swann Novel Cancer Therapeutics: Roundtable Conference on May 20, 2009

    About Dendreon

    Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel th
    '/>"/>

    SOURCE Dendreon Corporation
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
    2. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
    3. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
    4. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
    5. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
    6. Dendreon Reports Third Quarter 2008 Financial Results
    7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
    8. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
    9. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
    10. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
    11. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... July 29, 2014 Human Longevity, Inc. (HLI), ... focused on extending the healthy, high performance human life ... , Ph.D., an expert in machine learning and machine ... to HLI from Google where he was Distinguished Research ... report directly to HLI Co-Founder and CEO, J. ...
    (Date:7/29/2014)... , July 29, 2014  Pomerantz LLP is ... Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On July 29, 2014, Impax Laboratories, Inc. ...
    (Date:7/29/2014)... PORTLAND, Oregon , July 29, 2014 ... titled, "Global surgical equipment market (types, applications and geography) ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... expected to reach $12.1 billion by 2020 registering a ... Due to the breakthrough achieved by the electro surgical ...
    (Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready for business, and ... Center @3401 , a collaborative effort of Drexel University ... help attract and nurture start-up businesses in the region, officially ... , The Innovation Center @3401 (ic@3401), which is located at ... home of DreamIt Ventures and Point.io ...
    Breaking Biology Technology:Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3
    ... Research Foundation has licensed the California immunological research ... WARF's stem cell patents, Chemicon's parent company Serologicals ... to WARF's portfolio of stem cell technologies, which were ... . , ,Jeff Linton, president of Chemicon, said ...
    ... Platypus Technologies of suburban Madison has received ... for $200,000 from the National Cancer Institute. The grant ... rapid quantification of protein activity, useful for cancer research. ... II SBIR grant for $2.14 million from the National ...
    ... Customer Potential Management , a developer of databases and ... management solution has been implemented at the Michigan hospital ... the CRM solution to promote its collaboration with the ... with oncologists from both hospitals. While market research said ...
    Cached Biology Technology:WARF signs stem cell agreement with California firm 2
    (Date:7/28/2014)... the U.S. Food and Drug Administration (FDA) for other ... pathogens inside human cells, including those that cause Legionnaires, ... in mBio , the online open-access journal of ... of identifying non-antibiotic drugs that could one day help ... on the list inhibit the growth of at least ...
    (Date:7/28/2014)... States have a circulatory problem of the legs called ... even require surgery in serious cases. This disease can ... limb amputation. , At The University of Texas Health ... a non-surgical preventative treatment in a mouse model of ... circulation. Their proof-of-concept study appears in the journal ...
    (Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
    Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
    ... genomics initiative ever undertaken an international effort to ... Earth will be officially activated this week. , ... launched by the Minister of Research and Innovation, Glen ... Saturday, September 25 at 6:30 p.m. , By enabling ...
    ... Contrary to a thousand face cream adverts, the secret of ... Dr. Carlos Herrera, a Professor of Research at the Consejo ... the withering action of flowers may have evolved to protect ... issue of the Annals of Botany ( http://dx.doi.org/10.1093/aob/mcq160 ...
    ... objects in a new computer program designed to give people ... thought the ease of the using the program,s automatic mode ... many participants in a pilot study didn,t like it because ... mode, which requires them to think several steps ahead and ...
    Cached Biology News:Building a digital library for life on Earth 2Robotic arm's big flaw: Patients say it's 'too easy' 2
    ... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
    ... Maximize the value of your microarray data ... support you need from consultation to extensive ... date methods. Utilize our expertise in combination ... from your own microarray experiments., ,Normalization and ...
    BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
    ... of Flight Mass Analyzer for superior sensitivity, mass accuracy, and resolving ... m/z, * Precursor ion selection range: 150 - 4000 m/z, * ... with internal reference, * Dynamic range: 4 orders of magnitude ... ...
    Biology Products: